Gene Therapy Clinical Trials
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia
The overall aim of this study is to assess the efficacy and safety of AS1411, over a range of doses, when combined with cytarabine, in the treatment of patients with primary refractory or relapsed acute myeloid leukemia (AML).
Stanford is currently not accepting patients for this trial.
Intervention(s):
- drug: AS1411
Eligibility
Inclusion Criteria:
- primary refractory or relapsed AML
- confirmed diagnosis of AML (de novo or secondary) as defined by WHO classification
(Vardiman 2002)
- aged at least 18 years
Exclusion Criteria:
- initial diagnosis of acute promyelocytic leukemia as defined by
French-American-British criteria (Bennett 1976)
- patient in blast crisis stage of chronic myeloid leukemia
- received high-dose cytarabine (total cumulative dose of >6g/m sq)in last 6 months
- interval of <6 months between first onset of last complete remission and current
relapse
- those with primary refractory leukemia who have received more than three previous
induction cycles
- relapsed patients who have received more than three previous treatment regimens
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Richa Rajwanshi
6507364031
Not Recruiting